Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Stock Competitors & Peer Comparison
See AUPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AUPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AUPH | $16.90 | -0.35% | 2.2B | 16.57 | $1.02 | N/A |
| VRTX | $508.34 | -1.55% | 129B | 26.70 | $19.03 | N/A |
| REGN | $784.85 | -0.58% | 80.9B | 17.20 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $990.32 | -0.55% | 61.6B | 89.38 | $11.08 | N/A |
| MRNA | $154.04 | -2.55% | 61.1B | -18.90 | -$8.15 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $190.95 | -3.04% | 40.6B | -21.64 | -$8.82 | N/A |
| RVMDW | $9.64 | -6.36% | 38.3B | -1.11 | -$8.82 | N/A |
| ONC | $350.84 | -0.74% | 37.5B | 61.77 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
AUPH vs VRTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while VRTX trades at $508.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas VRTX's P/E ratio is 26.70. In terms of profitability, AUPH's ROE is +0.59%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, AUPH is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
AUPH vs REGN Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while REGN trades at $784.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas REGN's P/E ratio is 17.20. In terms of profitability, AUPH's ROE is +0.59%, compared to REGN's ROE of +0.14%. Regarding short-term risk, AUPH is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
AUPH vs VRNA Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas VRNA's P/E ratio is -102.80. In terms of profitability, AUPH's ROE is +0.59%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, AUPH is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
AUPH vs ARGX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ARGX trades at $990.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ARGX's P/E ratio is 89.38. In terms of profitability, AUPH's ROE is +0.59%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, AUPH is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
AUPH vs MRNA Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MRNA trades at $154.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MRNA's P/E ratio is -18.90. In terms of profitability, AUPH's ROE is +0.59%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, AUPH is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check MRNA's competition here
Seagen Inc. (NASDAQ: SGEN)
AUPH vs SGEN Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas SGEN's P/E ratio is -57.19. In terms of profitability, AUPH's ROE is +0.59%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, AUPH is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
AUPH vs RVMD Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RVMD trades at $190.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RVMD's P/E ratio is -21.64. In terms of profitability, AUPH's ROE is +0.59%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, AUPH is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
AUPH vs RVMDW Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RVMDW trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, AUPH's ROE is +0.59%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, AUPH is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
AUPH vs ONC Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ONC trades at $350.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ONC's P/E ratio is 61.77. In terms of profitability, AUPH's ROE is +0.59%, compared to ONC's ROE of +0.14%. Regarding short-term risk, AUPH is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
AUPH vs ALNY Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ALNY trades at $239.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ALNY's P/E ratio is 44.24. In terms of profitability, AUPH's ROE is +0.59%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, AUPH is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
AUPH vs ROIV Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ROIV trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ROIV's P/E ratio is -37.84. In terms of profitability, AUPH's ROE is +0.59%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, AUPH is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
AUPH vs INSM Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, INSM has a market cap of 26B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while INSM trades at $120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas INSM's P/E ratio is -29.20. In terms of profitability, AUPH's ROE is +0.59%, compared to INSM's ROE of -1.11%. Regarding short-term risk, AUPH is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
AUPH vs INCY Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while INCY trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas INCY's P/E ratio is 16.84. In terms of profitability, AUPH's ROE is +0.59%, compared to INCY's ROE of +0.30%. Regarding short-term risk, AUPH is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
AUPH vs BNTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while BNTX trades at $96.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas BNTX's P/E ratio is -12.46. In terms of profitability, AUPH's ROE is +0.59%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, AUPH is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
AUPH vs GMAB Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while GMAB trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas GMAB's P/E ratio is 26.18. In terms of profitability, AUPH's ROE is +0.59%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, AUPH is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
AUPH vs UTHR Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while UTHR trades at $494.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas UTHR's P/E ratio is 17.70. In terms of profitability, AUPH's ROE is +0.59%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, AUPH is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
AUPH vs BGNE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas BGNE's P/E ratio is -22.55. In terms of profitability, AUPH's ROE is +0.59%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, AUPH is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
AUPH vs DNA-WT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, AUPH's ROE is +0.59%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, AUPH is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
AUPH vs JAZZ Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while JAZZ trades at $240.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, AUPH's ROE is +0.59%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, AUPH is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
AUPH vs NBIX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while NBIX trades at $146.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas NBIX's P/E ratio is 21.13. In terms of profitability, AUPH's ROE is +0.59%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, AUPH is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
AUPH vs ASND Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ASND trades at $236.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ASND's P/E ratio is -97.82. In terms of profitability, AUPH's ROE is +0.59%, compared to ASND's ROE of +1.90%. Regarding short-term risk, AUPH is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
AUPH vs EXEL Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while EXEL trades at $58.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas EXEL's P/E ratio is 16.67. In terms of profitability, AUPH's ROE is +0.59%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, AUPH is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
AUPH vs SMMT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while SMMT trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas SMMT's P/E ratio is -15.94. In terms of profitability, AUPH's ROE is +0.59%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, AUPH is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
AUPH vs HALO Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while HALO trades at $112.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas HALO's P/E ratio is 20.98. In terms of profitability, AUPH's ROE is +0.59%, compared to HALO's ROE of +1.81%. Regarding short-term risk, AUPH is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
AUPH vs BBIO Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while BBIO trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas BBIO's P/E ratio is -17.81. In terms of profitability, AUPH's ROE is +0.59%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, AUPH is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
AUPH vs KRTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas KRTX's P/E ratio is -28.09. In terms of profitability, AUPH's ROE is +0.59%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, AUPH is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
AUPH vs BMRN Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas BMRN's P/E ratio is 30.74. In terms of profitability, AUPH's ROE is +0.59%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, AUPH is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
AUPH vs MDGL Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MDGL trades at $531.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MDGL's P/E ratio is -41.52. In terms of profitability, AUPH's ROE is +0.59%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, AUPH is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
AUPH vs TECH Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TECH trades at $72.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TECH's P/E ratio is 37.30. In terms of profitability, AUPH's ROE is +0.59%, compared to TECH's ROE of +0.09%. Regarding short-term risk, AUPH is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
AUPH vs RNAM Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RNAM's P/E ratio is -17.39. In terms of profitability, AUPH's ROE is +0.59%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, AUPH is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
AUPH vs AXSM Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while AXSM trades at $207.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas AXSM's P/E ratio is -54.25. In terms of profitability, AUPH's ROE is +0.59%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, AUPH is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
AUPH vs TWST Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TWST trades at $166.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TWST's P/E ratio is -75.22. In terms of profitability, AUPH's ROE is +0.59%, compared to TWST's ROE of -0.30%. Regarding short-term risk, AUPH is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check TWST's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
AUPH vs KRYS Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while KRYS trades at $336.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas KRYS's P/E ratio is 42.19. In terms of profitability, AUPH's ROE is +0.59%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, AUPH is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check KRYS's competition here
10x Genomics, Inc. (NASDAQ: TXG)
AUPH vs TXG Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TXG trades at $76.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TXG's P/E ratio is -129.83. In terms of profitability, AUPH's ROE is +0.59%, compared to TXG's ROE of -0.09%. Regarding short-term risk, AUPH is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check TXG's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
AUPH vs KYMR Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while KYMR trades at $117.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas KYMR's P/E ratio is -36.80. In terms of profitability, AUPH's ROE is +0.59%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, AUPH is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
AUPH vs RXDX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RXDX's P/E ratio is -56.47. In terms of profitability, AUPH's ROE is +0.59%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, AUPH is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
AUPH vs ARWR Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ARWR trades at $66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ARWR's P/E ratio is -29.55. In terms of profitability, AUPH's ROE is +0.59%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, AUPH is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
AUPH vs PTGX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while PTGX trades at $143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas PTGX's P/E ratio is 138.83. In terms of profitability, AUPH's ROE is +0.59%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, AUPH is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
AUPH vs NUVL Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas NUVL's P/E ratio is -21.79. In terms of profitability, AUPH's ROE is +0.59%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, AUPH is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
AUPH vs CRNX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CRNX's P/E ratio is -16.86. In terms of profitability, AUPH's ROE is +0.59%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, AUPH is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
AUPH vs IBRX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while IBRX trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas IBRX's P/E ratio is -8.74. In terms of profitability, AUPH's ROE is +0.59%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, AUPH is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
AUPH vs IMGN Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas IMGN's P/E ratio is -111.55. In terms of profitability, AUPH's ROE is +0.59%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, AUPH is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
AUPH vs TGTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TGTX trades at $56.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TGTX's P/E ratio is 20.61. In terms of profitability, AUPH's ROE is +0.59%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, AUPH is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check TGTX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
AUPH vs CYTK Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CYTK trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CYTK's P/E ratio is -9.53. In terms of profitability, AUPH's ROE is +0.59%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, AUPH is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
AUPH vs CAI Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CAI trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CAI's P/E ratio is 84.24. In terms of profitability, AUPH's ROE is +0.59%, compared to CAI's ROE of +0.19%. Regarding short-term risk, AUPH is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
AUPH vs PCVX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while PCVX trades at $58.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas PCVX's P/E ratio is -7.62. In terms of profitability, AUPH's ROE is +0.59%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, AUPH is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
AUPH vs BPMC Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas BPMC's P/E ratio is -51.58. In terms of profitability, AUPH's ROE is +0.59%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, AUPH is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
AUPH vs APGE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas APGE's P/E ratio is -31.19. In terms of profitability, AUPH's ROE is +0.59%, compared to APGE's ROE of -0.30%. Regarding short-term risk, AUPH is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
AUPH vs PRAX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while PRAX trades at $298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas PRAX's P/E ratio is -23.12. In terms of profitability, AUPH's ROE is +0.59%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, AUPH is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
AUPH vs CERE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CERE's P/E ratio is -16.47. In terms of profitability, AUPH's ROE is +0.59%, compared to CERE's ROE of -0.72%. Regarding short-term risk, AUPH is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
AUPH vs SYRE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while SYRE trades at $90.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas SYRE's P/E ratio is -46.28. In terms of profitability, AUPH's ROE is +0.59%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, AUPH is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check SYRE's competition here
Abivax S.A. (NASDAQ: ABVX)
AUPH vs ABVX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ABVX trades at $105.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ABVX's P/E ratio is -55.06. In terms of profitability, AUPH's ROE is +0.59%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, AUPH is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
AUPH vs IMVT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while IMVT trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas IMVT's P/E ratio is -13.10. In terms of profitability, AUPH's ROE is +0.59%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, AUPH is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
AUPH vs MTSR Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MTSR's P/E ratio is -23.58. In terms of profitability, AUPH's ROE is +0.59%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, AUPH is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
AUPH vs IONS Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while IONS trades at $44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas IONS's P/E ratio is -25.84. In terms of profitability, AUPH's ROE is +0.59%, compared to IONS's ROE of -1.11%. Regarding short-term risk, AUPH is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check IONS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
AUPH vs BLTE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while BLTE trades at $170.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas BLTE's P/E ratio is -91.42. In terms of profitability, AUPH's ROE is +0.59%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, AUPH is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
AUPH vs MRUS Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MRUS's P/E ratio is -17.05. In terms of profitability, AUPH's ROE is +0.59%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, AUPH is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
AUPH vs ACLX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ACLX's P/E ratio is -28.27. In terms of profitability, AUPH's ROE is +0.59%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, AUPH is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check ACLX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
AUPH vs RYTM Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RYTM trades at $97.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RYTM's P/E ratio is -31.42. In terms of profitability, AUPH's ROE is +0.59%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, AUPH is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check RYTM's competition here
CG Oncology Inc. (NASDAQ: CGON)
AUPH vs CGON Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CGON trades at $74.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CGON's P/E ratio is -27.74. In terms of profitability, AUPH's ROE is +0.59%, compared to CGON's ROE of -0.25%. Regarding short-term risk, AUPH is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
AUPH vs RETA Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RETA's P/E ratio is -66.29. In terms of profitability, AUPH's ROE is +0.59%, compared to RETA's ROE of +0.47%. Regarding short-term risk, AUPH is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
AUPH vs CNTA Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CNTA's P/E ratio is -22.63. In terms of profitability, AUPH's ROE is +0.59%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, AUPH is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
AUPH vs TVTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TVTX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TVTX's P/E ratio is -139.47. In terms of profitability, AUPH's ROE is +0.59%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, AUPH is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check TVTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
AUPH vs ORKA Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ORKA trades at $94.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ORKA's P/E ratio is -48.95. In terms of profitability, AUPH's ROE is +0.59%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, AUPH is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ORKA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
AUPH vs LGND Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while LGND trades at $283.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas LGND's P/E ratio is 31.12. In terms of profitability, AUPH's ROE is +0.59%, compared to LGND's ROE of +0.20%. Regarding short-term risk, AUPH is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
AUPH vs CDTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CDTX's P/E ratio is -19.77. In terms of profitability, AUPH's ROE is +0.59%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, AUPH is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
AUPH vs MIRM Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MIRM trades at $91.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MIRM's P/E ratio is -6.31. In terms of profitability, AUPH's ROE is +0.59%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, AUPH is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check MIRM's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
AUPH vs SRRK Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while SRRK trades at $46.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas SRRK's P/E ratio is -13.52. In terms of profitability, AUPH's ROE is +0.59%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, AUPH is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
AUPH vs ABCM Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, AUPH's ROE is +0.59%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, AUPH is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
AUPH vs ISEE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ISEE's P/E ratio is -22.44. In terms of profitability, AUPH's ROE is +0.59%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, AUPH is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
AUPH vs PTCT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while PTCT trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas PTCT's P/E ratio is -28.06. In terms of profitability, AUPH's ROE is +0.59%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, AUPH is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
AUPH vs CRSP Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CRSP trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CRSP's P/E ratio is -11.88. In terms of profitability, AUPH's ROE is +0.59%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, AUPH is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check CRSP's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
AUPH vs DNTH Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while DNTH trades at $96.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas DNTH's P/E ratio is -23.33. In terms of profitability, AUPH's ROE is +0.59%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, AUPH is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
AUPH vs COGT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while COGT trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas COGT's P/E ratio is -14.93. In terms of profitability, AUPH's ROE is +0.59%, compared to COGT's ROE of -0.73%. Regarding short-term risk, AUPH is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check COGT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
AUPH vs APLS Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas APLS's P/E ratio is 38.35. In terms of profitability, AUPH's ROE is +0.59%, compared to APLS's ROE of +0.40%. Regarding short-term risk, AUPH is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
AUPH vs DFTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while DFTX trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas DFTX's P/E ratio is N/A. In terms of profitability, AUPH's ROE is +0.59%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, AUPH is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check DFTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
AUPH vs ERAS Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ERAS trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ERAS's P/E ratio is -15.88. In terms of profitability, AUPH's ROE is +0.59%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, AUPH is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ERAS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
AUPH vs EWTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while EWTX trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas EWTX's P/E ratio is -24.50. In terms of profitability, AUPH's ROE is +0.59%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, AUPH is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
AUPH vs PBLS Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while PBLS trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas PBLS's P/E ratio is -47.42. In terms of profitability, AUPH's ROE is +0.59%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, AUPH is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check PBLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
AUPH vs TERN Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TERN's P/E ratio is -51.41. In terms of profitability, AUPH's ROE is +0.59%, compared to TERN's ROE of -0.20%. Regarding short-term risk, AUPH is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
AUPH vs ACAD Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ACAD trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ACAD's P/E ratio is 12.29. In terms of profitability, AUPH's ROE is +0.59%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, AUPH is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
AUPH vs IOVA Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while IOVA trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas IOVA's P/E ratio is -14.04. In terms of profitability, AUPH's ROE is +0.59%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, AUPH is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check IOVA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
AUPH vs ADPT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ADPT trades at $28.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ADPT's P/E ratio is -69.63. In terms of profitability, AUPH's ROE is +0.59%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, AUPH is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
AUPH vs FOLD Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas FOLD's P/E ratio is -161.00. In terms of profitability, AUPH's ROE is +0.59%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, AUPH is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
AUPH vs AKRO Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas AKRO's P/E ratio is -14.57. In terms of profitability, AUPH's ROE is +0.59%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, AUPH is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
AUPH vs ALPN Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ALPN's P/E ratio is -101.52. In terms of profitability, AUPH's ROE is +0.59%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, AUPH is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
AUPH vs MANE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MANE trades at $106.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MANE's P/E ratio is -33.96. In terms of profitability, AUPH's ROE is +0.59%, compared to MANE's ROE of -0.38%. Regarding short-term risk, AUPH is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check MANE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
AUPH vs TLX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while TLX trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas TLX's P/E ratio is 131.42. In terms of profitability, AUPH's ROE is +0.59%, compared to TLX's ROE of +0.07%. Regarding short-term risk, AUPH is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check TLX's competition here
Opthea Limited (NASDAQ: OPT)
AUPH vs OPT Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas OPT's P/E ratio is -1.52. In terms of profitability, AUPH's ROE is +0.59%, compared to OPT's ROE of +1.18%. Regarding short-term risk, AUPH is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
AUPH vs PRTC Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas PRTC's P/E ratio is -3.78. In terms of profitability, AUPH's ROE is +0.59%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, AUPH is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
AUPH vs RLAY Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RLAY trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RLAY's P/E ratio is -12.00. In terms of profitability, AUPH's ROE is +0.59%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, AUPH is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
AUPH vs MRTX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas MRTX's P/E ratio is -4.82. In terms of profitability, AUPH's ROE is +0.59%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, AUPH is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
AUPH vs CELC Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CELC trades at $80.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CELC's P/E ratio is -18.75. In terms of profitability, AUPH's ROE is +0.59%, compared to CELC's ROE of -3.51%. Regarding short-term risk, AUPH is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check CELC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
AUPH vs ABCL Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while ABCL trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas ABCL's P/E ratio is -23.39. In terms of profitability, AUPH's ROE is +0.59%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, AUPH is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
AUPH vs CPRX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CPRX's P/E ratio is 12.30. In terms of profitability, AUPH's ROE is +0.59%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, AUPH is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check CPRX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
AUPH vs XENE Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while XENE trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas XENE's P/E ratio is -8.46. In terms of profitability, AUPH's ROE is +0.59%, compared to XENE's ROE of -0.44%. Regarding short-term risk, AUPH is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
AUPH vs AMLX Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while AMLX trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas AMLX's P/E ratio is -22.63. In terms of profitability, AUPH's ROE is +0.59%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, AUPH is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for AUPH.Check AMLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
AUPH vs RYZB Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas RYZB's P/E ratio is -57.86. In terms of profitability, AUPH's ROE is +0.59%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, AUPH is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
AUPH vs CBAY Comparison September 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AUPH stands at 2.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, AUPH is priced at $16.90 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AUPH currently has a P/E ratio of 16.57, whereas CBAY's P/E ratio is -32.81. In terms of profitability, AUPH's ROE is +0.59%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, AUPH is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for AUPH.Check CBAY's competition here